DUBLIN — Irish drug maker Elan Corp. is paying about $380 million to buy one drug maker and a large stake in another, the company said.
Elan announced plans to buy Vienna-based AOP Orphan Pharmaceuticals for about $340 million, a company that specializes in drugs for rare conditions in a variety of areas, including cancer, neurology and metabolic disorders. Elan also paid an initial $40 million to buy a 48% stake in Newbridge Pharmaceuticals, based in Dubai, United Arab Emirates. Elan will have the option to buy the rest of the company for $244 million by 2015.
"Our proposed package of transactions is designed to create a balance of risk with the benefit of diversification to produce long-term growth in income and value," Elan CEO Kelly Martin said.
Get connected and follow us on LinkedIn for the most in-depth coverage of drug store news. Join the conversation.